Antituberculosis: Synthesis and antimycobacterial activity of novel benzimidazole derivatives

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Keng Yoon, Yeong ^a   Ashraf Ali, Mohamed ^a,b,c   Choon, Tan Soo ^a   Ismail, Rusli ^d   Chee Wei, Ang ^a   Suresh Kumar, Raju ^e,f   Osman, Hasnah ^e   Beevi, Farzana ^c  

^a INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^b Alwar Pharmacy College   (India)

^c Sunrise University   (India)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e SCHOOL OF PHYSICS   (Malaysia)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUORO 3 NITROBENZOIC ACID; 4-FLUORO-3-NITROBENZOIC ACID; BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; NITROBENZOIC ACID DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; CHEMISTRY; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BENZIMIDAZOLES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROBENZOATES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 84893797294     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/926309     Document Type: Article

References (14)

1. Dutt A. K., Stead W. W., Epidemiology and Host Factors: Tuberculosis and Nontuberculous Mycobacterial Infection 1999 4th Philadelphia, Pa, USA W.B. Saunders Company
2. World Health Organization,. WHO Report 2011: Global Tuberculosis Control., WHO/HTM/TB/2011. 16
3. Snider D. E. Jr., Roper W. L., The new tuberculosis. The New England Journal of Medicine 1992 326 10 703 705 2-s2.0-0026500715
4. Bass J. B. Jr., Farer L. S., Hopewell P. C., O'Brien R., Jacobs R. F., Ruben F., Snider D. E. Jr., Thornton G., Treatment of tuberculosis and tuberculosis infection in adults and children. Ameri (Pubitemid 24147082)
5. Koul A., Arnoult E., Lounis N., Guillemont J., Andries K., The challenge of new drug discovery for tuberculosis. Nature 2011 469 7331 483 490 2-s2.0-79251589638 10.1038/nature09657
6. Komazin G., Ptak R. G., Emmer B. T., Townsend L. B., Drach J. C., Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. Nucleosides, Nucleotides and Nucleic Acids 2003 22 5-8 1725 1727 2-s2.0-0141707798 10.1081/NCN-120023123 (Pubitemid 37139484)
7. Mader M., de Dios A., Shih C., Bonjouklian R., Li T., White W., de Uralde B. L., Sánchez-Martinez C., del Prado M., Jaramillo C., de Diego E., Martín Cabrejas L. M., Dominguez C., Montero C., Shepherd T., Dally R., Toth J. E., Chatterjee A., Pleite S., Blanco-Urgoiti J., Perez L., Barberis M., Lorite M. J., Jambrina E., Nevill C. R. Jr., Lee P. A., Schultz R. C., Wolos J. A., Li L. C., Campbell R. M., Anderson B. D., Imidazolyl benzimidazoles and imidazo[4,5- b ]pyridines as potent p38 α MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorganic and Medicinal Chemistry Letters 2008 18 1 179 183 2-s2.0-37549052157 10.1016/j.bmcl.2007.10. 106
8. Rao A., Chimirri A., De Clercq E., Monforte A. M., Monforte P., Pannecouque C., Zappalà M., Synthesis and anti-HIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Farmaco 2002 57 10 819 823 2-s2.0-1842866611 10.1016/S0014-827X(02)01300-9 (Pubitemid 35440977)
9. Evans B. E., Rittle K. E., Bock M. G., DiPardo R. M., Freidinger R. M., Whitter W. L., Lundell G. F., Veber D. F., Anderson P. S., Chang R. S. L., Lotti V. J., Cerino D. J., Chen T. B., Kling P. J., Kunkel K. A., Springer J. P., Hirshfield J., Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. Journal of Medicinal Chemistry 1988 31 12 2235 2246 2-s2.0-0024239320 (Pubitemid 19001640)
10. Pieroni M., Tipparaju S. K., Lun S., Song Y., Sturm A. W., Bishai W. R., Kozikowski A. P., Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. ChemMedChem 2011 6 2 334 342 2-s2.0-79251569911 10.1002/cmdc.201000490
11. Lilienkampf A., Pieroni M., Wan B., Wang Y., Franzblau S. G., Kozikowski A. P., Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. A potent and selective series for further drug development. Journal of Medicinal Chemistry 2010 53 2 678 688 2-s2.0-77249153741 10.1021/jm901273n
12. Foks H., Pancechowska-Ksepko D., Kuzmierkiewicz W., Zwolska Z., Augustynowicz-Kopec E., Janowiec M., Synthesis and tuberculostatic activity of new benzimidazole derivatives. Chemistry of Heterocyclic Compounds 2006 42 5 611 614 2-s2.0-33748210874 10.1007/s10593-006-0135-x
13. Collins L. A., Franzblau S. G., Microplate Alamar blue assay versus BACTEC 460 system for high- throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrobial Agents and Chemotherapy 1997 41 5 1004 1009 2-s2.0-0030903133 (Pubitemid 27194176)
14. Torres-Gómez H., Hernández-Núñez E., León-Rivera I., Guerrero-Alvarez J., Cedillo-Rivera R., Moo-Puc R., Argotte-Ramos R., Carmen Rodríguez-Gutiérrez M. D., Chan-Bacab M. J., Navarrete-Vázquez G., Design, synthesis and in vitro antiprotozoal activity of benzimidazole-pentamidine hybrids. Bioorganic and Medicinal Chemistry Letters 2008 18 11 3147 3151 2-s2.0-44249094176 10.1016/j.bmcl.2008. 05.009 (Pubitemid 351721012)